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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Ultrasonography has long been recognized as a useful tool for detecting
hepatic steatosis in clinical practice. However, whether it can assess the severity of hepatic
steatosis and which factors affect its diagnostic accuracy remain unclear.
Methods: A total of 171 patients with various causes of hepatitis undergoing liver biopsies were
retrospectively reviewed. The clinical, serologic data and ultrasonographical findings were
recorded. Hepatic steatosis was graded as negative, mild, moderate, or severe by ultrasonog-
raphy and histology. Histology was used as gold standard and the agreement rates were
calculated.
Results: Our data showed that the agreement rate of ultrasonography was 61.4% in assessing
the severity of hepatic steatosis and 74.3% in diagnosing hepatic steatosis compared with
histology (crude kappaZ 0.46 vs. 0.46). Using univariate analyses, body mass index and
histology activity index score were associated with the agreement in assessing the severity
of hepatic steatosis (pZ 0.008 and 0.035), whereas Ishak fibrosis score had a trend associa-
tion (pZ 0.066). Multivariate analyses indicated that age, body mass index, and Ishak fibrosis
score could affect the agreement (odds ratioZ 0.72, 0.89, and 1.41; 95% confidence inter-
valZ 0.54e0.97, 0.83e0.97, and 1.1e1.8).ave no conflicts of interest relevant to this article.
titute of Clinical Medicine, National Taiwan University College of Medicine, 1 Chang-Te Street, Taipei
(J.-H. Kao).
ight ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
2.07.004
250 C.-C. Wang et al.Conclusion: Ultrasonography could assess the severity of hepatic steatosis with moderate
accuracy. Obese patients are difficult ultrasonographically. In addition, age and hepatic
fibrosis could affect the performance of ultrasonography in assessing the severity of hepatic
steatosis.
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Hepatic steatosis is commonly observed in daily clinical
practice, and the prevalence of hepatic steatosis is
increasing in parallel with the pandemics of obesity and
type 2 diabetes mellitus.1 Hepatic steatosis also frequently
coexists with chronic hepatitis C, alcoholic liver disease or
nonalcoholic fatty liver disease (NAFLD), which has the
potential to develop end-stage liver disease including
cirrhosis and liver cancer.2e5 In addition, patients with
NAFLD have a higher prevalence of metabolic syndrome and
increased risk of diabetes mellitus as well as cardiovascular
disease.6e14 Therefore, hepatic steatosis has been recog-
nized as an emerging global health threat.
The risk of metabolic syndrome has been reported to be
positively associated with the severity of hepatic steatosis
on ultrasonography.15 In addition, serum alanine amino-
transferase (ALT) abnormalities usually occur in patients
with more severe fatty liver.16 Taking these lines of
evidence together, accurate assessment of the severity of
hepatic steatosis can help practicing physicians to identify
earlier the risk of liver disease progression in patients.
Although needle biopsy remains the gold standard for
the diagnosis of hepatic steatosis, several disadvantages
have been discussed, such as possible biopsy danger,
different sampling area, or interobserver variability.17,18
Furthermore, it is invasive and often declined by patients.
Therefore, it is important for clinicians to develop reliable
and specific techniques for noninvasive detection and
quantification of hepatic steatosis.
On the basis of increased echogenicity of liver and the
presence of contrast as compared to adjacent organs such as
kidney, vascular wall, or diaphragm, ultrasonography is the
most commonly used modality in diagnosing hepatic stea-
tosis.19 However, the ability to make an accurate grading or
quantification is necessary for longitudinal follow-up of
disease progression and assessing the response to treat-
ment.20 Computed tomography and magnetic resonance
imaging have been evaluated for this purpose.21,22 Because
ultrasonography is cheaper andadds no increasedexposure to
radiation, it is the best candidate to be used in longitudinal
monitoring, if the diagnostic accuracy could be confirmed. In
this study, we thus retrospectively investigated whether
ultrasonography could assess the severity of hepatic steatosis
and factors influencing its diagnostic accuracy.Materials and methods
Patients and methods
A total of 171 patients with various causes of hepatitis
receiving liver biopsy between 2007 and 2009 in Tzu ChiGeneral Hospital were included in this study. The causes of
chronic liver disease were chronic hepatitis B in 61, chronic
hepatitis C in 88, hepatitis B and C coinfection in 9, and
other causes in 13 patients including 1 acute hepatitis
C infection, 1 drug induced hepatitis, 1 autoimmune
hepatitis, and 10 NAFLD. Demographic, clinical, serologic,
and biochemical data were obtained from each participant.
The ultrasonographical findings in terms of the severity of
hepatic steatosis (negative, mild, moderate, and severe)
were retrieved from medical records. Hepatic steatosis on
histology was categorized as negative (5%), mild (6e33%),
moderate (34e66%), or severe (>67%). Agreement was
defined as having the same results between ultrasono-
graphical and histological findings. The agreement rates in
the presence and severity of hepatic steatosis were sepa-
rately calculated. According to the presence or absence of
agreement, the participants were divided into agreement
and non-agreement groups. Variables including age, sex,
causes of hepatitis, ultrasound machines, operators, body
mass index (BMI), aspartate aminotransferase (AST), ALT,
creatinine, platelet count, white blood cell (WBC) count,
hemoglobin, histology activity index (HAI) score, and Ishak
fibrosis score were included in univariate and multivariate
analyses for their associations with the diagnostic accuracy
of ultrasonography.
Clinical features and biochemical examinations
We retrospectively collected information on age, sex, BMI,
creatinine, hemoglobin, WBC count, platelet count, and
ALT and AST levels. BMI was calculated as weight in kilo-
grams divided by height squared. The biochemical data
were measured by an autoanalyzer (Roche Analytics; Roche
Professional Diagnostics, Penzberg, Germany).
Ultrasound examination of the liver
All ultrasonograms were obtained with one of two units:
one (LOGIQ-5; GE, Medical System Ltd, Seoul, Korea) with
a 4-MHz electronic probe and the other (LOGIQ-7; GE,
Medical System Ltd, Seoul, Korea) with a 5-MHz electronic
probe. One of the ten hepatologists who were qualified and
well experienced in abdominal ultrasonography performed
the examinations. The technical parameters, including gain
adjustment, use of tissue harmonics, and use of harmonics,
were optimized on a case-by-case basis. Routine images
were recorded and saved on a PACS system. The severity of
hepatic steatosis was recorded as negative, mild,
moderate, or severe. If the echogenicity of the liver is the
same as that of the renal cortex, it is defined as negative
steatosis. A slight increase in liver echogenicity with clear
vascular wall and diaphragm defines mild steatosis. In
moderate steatosis, visualization of vascular wall and
Sonography in grading hepatic steatosis 251diaphragm was impaired and blurred. Severe steatosis was
recognized as marked increase brightness, far-field beam
attenuation of the posterior segment of the right lobe of
liver, and no visualization of vascular wall and
diaphragm.23,24
Histological evaluations of liver biopsy specimens
After we obtained written informed consent for the use of
clinical data and residual tissue, each patient without
contraindications for liver biopsies received an echo-guided
percutaneous liver biopsy from the right hepatic lobe using
an 18-gauge biopsy needle (Temno REF T1820; Cardi-
nalHealth, Dublin, Ireland). The sampling tissues were fixed
with formalin, embedded with paraffin, and stained with
hematoxylin and eosin. One experienced pathologist, who
was blinded to the clinical status of patients and results of
ultrasonography readings, evaluated the samples. Hepatic
steatosis on histology was categorized as negative (5%),
mild (6e33%), moderate (34e66%), or severe (>67%). The
staging of hepatic fibrosis was scored by Ishak fibrosis score,
which ranged from F0 to F6.
Ethical considerations
The study was performed in accordance with the principles
of the 1975 Declaration of Helsinki and approved by the
Ethical Committee of Buddhist Tzu-Chi General Hospital,
which waived the study design-specific informed consent.
Statistical analysis
The agreement rates were calculated by dividing the
number of occasions of complete agreement by the total
number of occasions. Weighted kappa statistics were used
to determine the degree of agreement after correction for
the agreement expected by chance.25 The kappa statistic
was interpreted as follows: less than 0, poor agreement;
0e0.2, slight agreement; 0.2e0.4, fair agreement;
0.4e0.6, moderate agreement; 0.6e0.8, substantial
agreement; 0.8e1, almost perfect agreement. Chi-square
and Student’s t-tests were used to compare whether
there was a significant difference in the frequencyTable 1 Agreement of the severity of hepatic steatosis betwee
Results of
ultrasonographical findings
N
Negative
N (%)
Negative 101 84 (82.3)
Mild 42 24 (57.1)
Moderate 25 3 (12.0)
Severe 3 0 (0.0)
(1) Agreements for the presence of steatosis between ultrasonograph
Crude kappaZ 0.46 (0.32e0.59).
Adjusted (for hepatologists) kappaZ 0.46 (95% CI, 0.33e0.58; test fo
(2) Agreements for the severity of steatosis between ultrasonographi
Crude kappaZ 0.46 (0.35e0.57).
Adjusted (for hepatologists) kappaZ 0.44 (95% CI, 0.35e0.54; test fodistributions and the means between agreement and non-
agreement groups. Univariate and multivariate logistic
regression analyses were used to measure the strength of
association between all parameters and agreement in
determining the presence of hepatic steatosis or assessing
the severity of hepatic steatosis, signified as odds ratio
(OR). Statistical analyses were performed using SAS 9.1 (SAS
Institute Inc., Cary, NC, USA). A p value of < 0.05 was
considered statistically significant.Results
Study population and demographic data
A total of 171 patients (100 men and 71 women with a mean
age of 49.0 13.2 years) were included for analysis. The
median interval between performing ultrasonography and
liver biopsy was 1 month (range: 0e10 months). Of the
total, the severity of hepatic steatosis on histological
findings was negative in 111, mild in 38, moderate in 10,
and severe in 12. Using Ishak fibrosis score, the severity of
fibrosis on histological findings was F0 in 2, F1 in 21, F2 in
21, F3 in 57, F4 in 23, F5 in 24, and F6 in 23, respectively.
Diagnostic accuracy of ultrasonography in the
presence and severity of hepatic steatosis
There were two patients with pathological severe steatosis
considered as negative on ultrasonographydthey were
chronic hepatitis C patients with severe fibrosis (Ishak
fibrosis score 6) and mild inflammation (HAI score of 5 and
6, respectively) on liver histology. The possible reason was
that hepatic fibrosis or inflammation could cause echogenic
abnormalities of liver on ultrasonography. Compared to
histological findings, the agreement rates of ultrasonog-
raphy were 74.3% (127/171, crude kappaZ 0.46) in
assessing the presence of hepatic steatosis and 61.4% (105/
171, crude kappaZ 0.46) in the severity of hepatic stea-
tosis (Table 1). Because the different cutoff points chosen
in four groups for hepatic steatosis may affect the agree-
ment, especially the three patients with severe steatosis in
ultrasonography, we combined “moderate to severe fattyn ultrasonographical and histological findings.
Results of histological findings
Mild Moderate Severe
N (%) N (%) N (%)
14 (14.3) 1 (1.0) 2 (2.0)
14 (33.3) 3 (7.1) 1 (2.4)
10 (40.0) 5 (20.0) 7 (28.0)
0 (0.0) 1 (33.3) 2 (66.7)
ical and histological findings.
r equal kappa: c2Z 5.97, pZ 0.54).
cal and histological findings.
r equal kappa: c2Z 4.13, pZ 0.76).
252 C.-C. Wang et al.liver” both in ultrasonography and histology to a group of
advanced fatty liver. Thus, there were 28 cases with
advanced fatty liver in ultrasonography and 22 cases in
histology. If the severity of hepatic steatosis was catego-
rized to three groups, the agreement rates of ultrasonog-
raphy in assessing the severity of hepatic steatosis
increased to 66.1% (113/171, crude kappaZ 0.59) (data not
shown).
Relationship among ultrasonographical steatosis,
HAI score, and Ishak fibrosis score
In this special population of acute or chronic liver diseases,
there was a trend toward lower HAI score or Ishak fibrosis
score in histology with increasing ultrasonographic steatosis
(Table 2).
Factors affecting the diagnostic accuracy of
ultrasonography in assessing the severity of hepatic
steatosis
By using univariate analyses, BMI and HAI score were asso-
ciated with agreement (pZ 0.008 and 0.035). In addition,
Ishak fibrosis scores had a trend association with agreement
(pZ 0.066). Age, sex, ultrasound machine, and the status
of viral hepatitis did not affect the agreement (Table 3).
Using multivariate analyses after adjustment with age, sex,
BMI, WBC, HAI score, and Ishak fibrosis score, we found that
Ishak fibrosis score, age, and BMI were associated with
agreement between ultrasonography and histology
(ORZ 0.72, 0.89 and 1.41; 95% confidence inter-
valZ 0.54e0.97, 0.83e0.97, and 1.1e1.8) (Table 4).
Discussion
Hepatic steatosis is an emerging clinical problem worldwide
and is the most common liver disease in Western coun-
tries.26 Ultrasonography is one of the most popular methods
to diagnose hepatic steatosis in daily practice.27,28 A recent
meta-analysis indicated that ultrasonography is a reliable
and accurate method in detecting moderate-severe fatty
liver comparable to histology.29 In this study, the diagnostic
accuracy of ultrasonography was 74.3% in the detection of
hepatic steatosis and 61.4% in assessing the severity of
hepatic steatosis compared to histology in patients with
different causes of hepatitis. In addition, age, BMI, andTable 2 Relationship among ultrasonographical steatosis, histo
Ultrasonographi
Histological Findings Negative Mild
HAI score
Median SD 5.47 1.78 4.45 2.04
Ishak fibrosis score
Median SD 3.85 1.53 2.98 1.52
HAIZ histology activity index; SDZ standard deviation.
a Analysis of variance (ANOVA).
b Test for trend across ordered groups.Ishak fibrosis score could affect the diagnostic accuracy of
ultrasonography in assessing the severity of hepatic
steatosis.
Because ultrasonography is operator-dependent and
interobserver variability dose exists, the accuracy of diag-
nosing hepatic steatosis varied in different populations or
studies. Previous studies found that several factors might
affect the ability of ultrasonography in diagnosing hepatic
steatosis. For example, morbidly obese patients had the
lowest accuracy, and advanced fibrosis could reduce the
sensitivity of ultrasonography.30 To the best of our knowl-
edge, this is the first study to elucidate the ability of
ultrasonography in assessing the severity of hepatic stea-
tosis. Age, BMI, and Ishak fibrosis score were identified to
be associated with the diagnostic accuracy in assessing the
severity of hepatic steatosis. Our data consistently
confirmed that a higher BMI could influence the diagnostic
ability of ultrasonography. Regarding the relationship
between age and diagnostic accuracy of ultrasonography,
the possible explanation was that the aging process could
change the echo texture of liver and/or kidney, and thus
lead to a poor performance of ultrasonography in older
populations.
A previous study had a similar population composed of
131 patients with chronic liver diseases.31 The authors
found that ultrasonographic diagnosis of fatty liver
correctly identified steatosis on biopsy in only 47.8% of the
patients, but 66% had significant fibrosis or significant
inflammation. They concluded that hepatic fibrosis or
inflammation was likely to cause echogenic abnormalities
of the liver. Our study also found 57.1% (24/42) of patients
with mild steatosis in ultrasonography without pathological
steatosis. Taking these lines of evidence, hepatic fibrosis or
inflammation could affect the diagnostic accuracy of
ultrasonography. Another study with 118 biopsy-proven
NAFLD patients found that the sensitivity of ultrasonog-
raphy was 100% for detecting moderate to severe histo-
logical steatosis in patients with mild histological fibrosis.
However, it reduced to 77.8% in those with advanced
histological fibrosis.32 Thus, advanced fibrosis could
decrease the sensitivity of ultrasonography for detecting
moderate to severe histological steatosis. In this study,
a higher agreement in advanced fibrosis was inconsistent
with previous studies. The advanced fibrosis could cause
echogenic abnormalities in ultrasonography. In addition,
a higher agreement found in the group without ultrasono-
graphical hepatic steatosis, which had higher Ishak fibrosis
score, may partly explain the findings of a higherlogically inflammatory, and fibrotic score.
cal steatosis
Moderate Severe p
0.0298a
4.64 2.60 3.67 1.53 <0.01b
<0.0001a
2.48 1.23 2.67 1.53 <0.01b
Table 3 Comparison of variables between agreement and non-agreement groups by chi-square test and Student’s t-test.
Severity of steatosis between ultrasonographical and histological findings
Non-agreement Agreement p
NZ 66 NZ 105
Age (y), mean (SD) 51.0 (12.9) 47.8 (13.2) 0.12
Male sex (n, %) 34 (51.5) 66 (62.9) 0.14
Body height (m), mean (SD)a 1.62 (0.11) 1.64 (0.09) 0.23
Body weight (kg), mean (SD) 69.3 (14.2) 67.0 (14.3) 0.30
BMI (kg/m2), mean (SD)a 26.6 (4.8) 24.6 (4.7) 0.008**
HBV positivity (n, %)b 27 (40.9) 43 (41.4) 0.96
HCV positivity (n, %)c 35 (53.9) 62 (59.6) 0.46
AST (IU/L), mean (SD) 80.3 (63.2) 92.6 (80.8) 0.30
ALT (IU/L) mean (SD) 135.8 (100.4) 144.2 (99.3) 0.59
Creatinine (mg/dL), mean (SD) 0.84 (0.65) 0.81 (0.38) 0.71
Platelet (K/mL), mean (SD) 183.1 (63.8) 176.7 (63.6) 0.52
HAI score, mean (SD) 4.53 (1.95) 5.11 (1.62) 0.035*
Ishak fibrosis score, mean (SD) 3.14 (1.52) 3.59 (1.59) 0.066þ
þ0.05< p< 0.1.
*0.01< p< 0.05.
**p< 0.01.
ALTZ alanine aminotransferase; ASTZ aspartate aminotransferase; BMIZ body mass index; HAIZ histology activity index;
HBVZ hepatitis B virus; HCVZ hepatitis C virus.
a Missing data for seven patients.
b Missing data for one patient.
c Missing data for two patients.
Sonography in grading hepatic steatosis 253agreement in advanced fibrosis. Therefore, further studies
are needed to confirm the impact of hepatic fibrosis on the
diagnostic accuracy of ultrasonography.
This study has several notable features. Although liver
biopsy is the gold standard in assessing the severity of
hepatic steatosis, interobserver variability dose exists. In
this study, one experienced pathologist, who was blinded to
the clinical status of the patients and results of ultrasono-
graphical findings, evaluated the samples. Therefore, the
possible bias due to interobserver variability could be
avoided. Furthermore, the quality of static images could
affect the decision of radiologists in the impression of
echogenicity. In our institute, ultrasonography was per-
formed by well experienced hepatologists. Therefore, the
variability between real-time and static images could be
reduced. In addition, our retrospective study could trulyTable 4 Multivariate-adjusted OR for the agreement of
the severity of steatosis between ultrasonographical and
histological findings.
Variables included in each model OR (95% CI)
Age (every 10-y increment) 0.72* (0.54e0.97)
BMI (every 1 kg/m2 increment) 0.89** (0.83e0.97)
Ishak fibrosis score
(each point increment)
1.41* (1.10e1.80)
Sex, age, BMI, HAI score, and Ishak fibrosis score were regarded
as potential determinants.
*0.01< p< 0.05.
**p< 0.01.
BMIZ body mass index; CIZ confidence interval; ORZ odds
ratio.reflect the ability of ultrasonography in assessing the
severity of hepatic steatosis in real-world clinical settings.
To the best of our knowledge, this is the first report to
investigate the factors affecting the ability of ultrasonog-
raphy in assessing the severity of hepatic steatosis after
adjustment with clinical parameters.
Several limitations should be acknowledged. First,
ultrasonographical parameters including bright liver echo,
hepatorenal contrast, far-field beam attenuation, and
blurred vascular wall are quite subjective. Second,
although the ultrasound examination was not performed at
the same time with liver biopsy, the mean interval of 2.16
months might affect the result of agreement minimally.
Third, the ultrasonographic examinations were not per-
formed by the same hepatologist, but one of ten hepatol-
ogists. Interobserver variability could exist among these
hepatologists. However, since the agreement was not
different among the 10 hepatologists (Table 1), the results
would not undermine our major conclusions.
In summary, ultrasonography could assess the severity of
hepatic steatosis with moderate accuracy compared to
histology. Obese patients are difficult to deal with ultra-
sonographically. In addition, age and hepatic fibrosis could
affect the performance of ultrasonography in assessing the
severity of hepatic steatosis.
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